Global Viral Vector Development Service 麻豆原创 Research Report 2025

Publication ID:

PB512248460

Publication Date:

January 2, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

The global market for Viral Vector Development Service was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Viral Vector Development Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Viral Vector Development Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Viral Vector Development Service in Pharmaceutical Manufacturers is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Viral Vector Development Service include UJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, UniQure, MassBiologics, FinVector, Thermo Fisher Scientific (Brammer Bio), Cell and Gene Therapy Catapult, Cobra Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Viral Vector Development Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector Development Service.
The Viral Vector Development Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Viral Vector Development Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector Development Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
UJIFILM Diosynth Biotechnologies
Sanofi
Spark Therapeutics
UniQure
MassBiologics
FinVector
Thermo Fisher Scientific (Brammer Bio)
Cell and Gene Therapy Catapult
Cobra Biologics
Segment by Type
Retroviral Vectors
Lentiviral Vectors
Adenoviral Vectors
Adeno-associated Viral Vectors
Others Viral Vectors
Segment by Application
Pharmaceutical Manufacturers
Biotechnology Companies
Research Institutes
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vector Development Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Viral Vector Development Service 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Retroviral Vectors
1.2.3 Lentiviral Vectors
1.2.4 Adenoviral Vectors
1.2.5 Adeno-associated Viral Vectors
1.2.6 Others Viral Vectors
1.3 麻豆原创 by Application
1.3.1 Global Viral Vector Development Service 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Manufacturers
1.3.3 Biotechnology Companies
1.3.4 Research Institutes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vector Development Service 麻豆原创 Perspective (2020-2031)
2.2 Global Viral Vector Development Service Growth Trends by Region
2.2.1 Global Viral Vector Development Service 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Viral Vector Development Service Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Viral Vector Development Service Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Viral Vector Development Service 麻豆原创 Dynamics
2.3.1 Viral Vector Development Service Industry Trends
2.3.2 Viral Vector Development Service 麻豆原创 Drivers
2.3.3 Viral Vector Development Service 麻豆原创 Challenges
2.3.4 Viral Vector Development Service 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral Vector Development Service Players by Revenue
3.1.1 Global Top Viral Vector Development Service Players by Revenue (2020-2025)
3.1.2 Global Viral Vector Development Service Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Viral Vector Development Service 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Viral Vector Development Service Revenue
3.4 Global Viral Vector Development Service 麻豆原创 Concentration Ratio
3.4.1 Global Viral Vector Development Service 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vector Development Service Revenue in 2024
3.5 Global Key Players of Viral Vector Development Service Head office and Area Served
3.6 Global Key Players of Viral Vector Development Service, Product and Application
3.7 Global Key Players of Viral Vector Development Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vector Development Service Breakdown Data by Type
4.1 Global Viral Vector Development Service Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Viral Vector Development Service Forecasted 麻豆原创 Size by Type (2026-2031)
5 Viral Vector Development Service Breakdown Data by Application
5.1 Global Viral Vector Development Service Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Viral Vector Development Service Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Viral Vector Development Service 麻豆原创 Size (2020-2031)
6.2 North America Viral Vector Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Viral Vector Development Service 麻豆原创 Size by Country (2020-2025)
6.4 North America Viral Vector Development Service 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Viral Vector Development Service 麻豆原创 Size (2020-2031)
7.2 Europe Viral Vector Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Viral Vector Development Service 麻豆原创 Size by Country (2020-2025)
7.4 Europe Viral Vector Development Service 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Viral Vector Development Service 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Viral Vector Development Service 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Viral Vector Development Service 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Viral Vector Development Service 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Viral Vector Development Service 麻豆原创 Size (2020-2031)
9.2 Latin America Viral Vector Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Viral Vector Development Service 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Viral Vector Development Service 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral Vector Development Service 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Viral Vector Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Viral Vector Development Service 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Viral Vector Development Service 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 UJIFILM Diosynth Biotechnologies
11.1.1 UJIFILM Diosynth Biotechnologies Company Details
11.1.2 UJIFILM Diosynth Biotechnologies Business Overview
11.1.3 UJIFILM Diosynth Biotechnologies Viral Vector Development Service Introduction
11.1.4 UJIFILM Diosynth Biotechnologies Revenue in Viral Vector Development Service Business (2020-2025)
11.1.5 UJIFILM Diosynth Biotechnologies Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Viral Vector Development Service Introduction
11.2.4 Sanofi Revenue in Viral Vector Development Service Business (2020-2025)
11.2.5 Sanofi Recent Development
11.3 Spark Therapeutics
11.3.1 Spark Therapeutics Company Details
11.3.2 Spark Therapeutics Business Overview
11.3.3 Spark Therapeutics Viral Vector Development Service Introduction
11.3.4 Spark Therapeutics Revenue in Viral Vector Development Service Business (2020-2025)
11.3.5 Spark Therapeutics Recent Development
11.4 UniQure
11.4.1 UniQure Company Details
11.4.2 UniQure Business Overview
11.4.3 UniQure Viral Vector Development Service Introduction
11.4.4 UniQure Revenue in Viral Vector Development Service Business (2020-2025)
11.4.5 UniQure Recent Development
11.5 MassBiologics
11.5.1 MassBiologics Company Details
11.5.2 MassBiologics Business Overview
11.5.3 MassBiologics Viral Vector Development Service Introduction
11.5.4 MassBiologics Revenue in Viral Vector Development Service Business (2020-2025)
11.5.5 MassBiologics Recent Development
11.6 FinVector
11.6.1 FinVector Company Details
11.6.2 FinVector Business Overview
11.6.3 FinVector Viral Vector Development Service Introduction
11.6.4 FinVector Revenue in Viral Vector Development Service Business (2020-2025)
11.6.5 FinVector Recent Development
11.7 Thermo Fisher Scientific (Brammer Bio)
11.7.1 Thermo Fisher Scientific (Brammer Bio) Company Details
11.7.2 Thermo Fisher Scientific (Brammer Bio) Business Overview
11.7.3 Thermo Fisher Scientific (Brammer Bio) Viral Vector Development Service Introduction
11.7.4 Thermo Fisher Scientific (Brammer Bio) Revenue in Viral Vector Development Service Business (2020-2025)
11.7.5 Thermo Fisher Scientific (Brammer Bio) Recent Development
11.8 Cell and Gene Therapy Catapult
11.8.1 Cell and Gene Therapy Catapult Company Details
11.8.2 Cell and Gene Therapy Catapult Business Overview
11.8.3 Cell and Gene Therapy Catapult Viral Vector Development Service Introduction
11.8.4 Cell and Gene Therapy Catapult Revenue in Viral Vector Development Service Business (2020-2025)
11.8.5 Cell and Gene Therapy Catapult Recent Development
11.9 Cobra Biologics
11.9.1 Cobra Biologics Company Details
11.9.2 Cobra Biologics Business Overview
11.9.3 Cobra Biologics Viral Vector Development Service Introduction
11.9.4 Cobra Biologics Revenue in Viral Vector Development Service Business (2020-2025)
11.9.5 Cobra Biologics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

UJIFILM Diosynth Biotechnologies
Sanofi
Spark Therapeutics
UniQure
MassBiologics
FinVector
Thermo Fisher Scientific (Brammer Bio)
Cell and Gene Therapy Catapult
Cobra Biologics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.